Insights Into Edwards Lifesciences (EW) Q4: Wall Street Projections for Key Metrics

Core Viewpoint - Edwards Lifesciences (EW) is expected to report a decline in quarterly earnings and revenues, with earnings per share projected at $0.55, down 14.1% year-over-year, and revenues forecasted at$ 1.36 billion, reflecting an 11.2% decrease [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts project 'Net Sales- Transcatheter Mitral and Tricuspid Therapies' to reach $93.28 million, a year-over-year increase of 66.6% [5] - 'Net Sales- Surgical Structural Heart' is expected to be$ 249.92 million, reflecting a slight increase of 0.7% year-over-year [5] - 'Net Sales- Transcatheter Aortic Valve Replacement' is forecasted at $1.02 billion, indicating a 3.9% increase from the previous year [6] Regional Sales Estimates - 'Net Sales- Europe' is estimated at$ 336.88 million, showing a year-over-year decline of 2.3% [6] - 'Net Sales- Outside of the United States' is projected to be $571.14 million, reflecting a decrease of 10.7% year-over-year [6] - 'Net Sales- United States' is expected to reach$ 837.97 million, down 6.3% from the previous year [7] - 'Net Sales- Japan' is forecasted at $84.00 million, indicating a significant decline of 25% year-over-year [7] - 'Net Sales- Rest of World' is projected to be$ 150.26 million, reflecting a decrease of 17.8% from the year-ago quarter [7] Stock Performance - Over the past month, Edwards Lifesciences shares have decreased by 2.8%, contrasting with the Zacks S&P 500 composite's increase of 2.1% [7] - The company holds a Zacks Rank 3 (Hold), suggesting its performance is likely to align with the overall market in the near term [7]